Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Amgen Inc.NASDAQ: AMGN

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin widens to 23.6%

Net margin was 23.6% in Q2 FY2026, up 8.0 pp from a year earlier. On a trailing-twelve-month basis it was 22.9%, up 4.0 pp year over year. Over 3 fiscal years it narrowed by 3.9 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 22 analysts of 32.4% for the fiscal year ending Dec 2026, up from 21.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
23.6%+2.5 pp QoQ
Last fiscal yearDec 2025
21.0%+8.8 pp YoY
LTMJun 2026
22.9%+4.0 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+8.0 pp-2.3 pp-10.3 pp
1 year+8.8 pp+11.4 pp+2.6 pp
3 years-3.9 pp+12.5 pp+16.4 pp
5 years+14.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
21.0%
Year-over-year change
+8.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How AMGN compares with its peers on the latest reported figures

  • AMGN's LTM Jun 2026 net margin of 22.9% is the 3rd highest of the 10 companies compared; the peer median is 16.2%.
  • Its year-over-year change of +4.0 pp is the 4th highest of 10, against a peer median of +1.5 pp.
  • Over three fiscal years its change of -3.9 pp compares with a peer median of +3.6 pp.
AMGN Competitors Peer median
Net Margin for AMGN and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202633.5% +7.6 pp+9.8 pp
NVSNovartis AGLTM Jun 202622.9% -1.8 pp+9.6 pp
AMGNAmgen Inc.LTM Jun 202622.9% +4.0 pp-3.9 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202618.9% +8.3 pp+0.9 pp
AZNAstraZeneca PLCLTM Sep 202617.7% +1.5 pp+10.0 pp
JNJJohnson & JohnsonLTM Sep 202616.2% -11.1 pp+6.0 pp
ABBVAbbVie Inc.LTM Sep 202615.7% +11.7 pp-13.5 pp
GSKGSK plcLTM Jun 202614.5% +3.7 pp-33.5 pp
PFEPfizer Inc.LTM Jun 20266.8% -10.0 pp-18.6 pp
MRKMerck & Co., Inc.LTM Jun 20264.8% -21.0 pp+3.6 pp
Peer median (excluding AMGN) 16.2%+1.5 pp+3.6 pp

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.98B26.32B28.19B33.42B36.74B
Cost of Revenue6.45B6.41B8.42B12.86B10.73B
Gross Profit19.53B19.92B19.78B20.57B26.01B
Gross Margin75.2%75.7%70.1%61.5%70.8%
Research & Development6.32B4.43B4.78B5.96B6.97B
Selling, General & Admin5.37B5.41B6.18B7.1B7.05B
Operating Expenses11.89B10.35B11.84B13.31B15.34B
Depreciation & Amortization3.4B3.42B4.07B5.59B5.17B
EBITDA11.3B12.17B14.8B13.36B16.9B
EBITDA Margin43.5%46.2%52.5%40.0%46.0%
Operating Income7.64B9.57B7.9B7.26B10.68B
Operating Margin29.4%36.3%28.0%21.7%29.1%
Interest Income00000
Interest Expense1.2B1.41B2.88B3.16B2.76B
Other Income / Expenses(938M)(2.22B)(42M)(2.65B)(1.7B)
Income Before Tax6.7B7.35B7.86B4.61B8.98B
Pre-Tax Margin25.8%27.9%27.9%13.8%24.4%
Income Tax Expense808M794M1.14B519M1.27B
Net Income5.89B6.55B6.72B4.09B7.71B
Net Margin22.7%24.9%23.8%12.2%21.0%
EPS (Basic)10.3412.1812.567.6214.33
EPS (Diluted)10.2812.1112.497.5614.23
Weighted Avg Shares570M538M535M541M538M
Weighted Avg Shares (Diluted)573M541M538M541M542M

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.